Home

ROBERT L VAN NOSTRAND

CIK 1225198 · last filed 2026-01-09

ROBERT L VAN NOSTRAND is a corporate insider who has filed 138 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for SLS, was dated Jan 9, 2026. Across all open-market trades the lifetime net is −$5.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.14M

Companies

6

Total Filings

138

Lifetime Open-Market Net

-$5.28M

Filer Profile

Reported Address
C/O ACHILLION PHARMACEUTICALS, INC.
300 GEORGE STREET
NEW HAVEN, CT 06511
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SLS Director 82,900 $13.70 $1.14M $14.8K 11 2026-01-09
Intra-Cellular Therapies, Inc. (ITCI) Delisted Director 0 $131.87 $0 -$5.32M 59 2025-04-02
YIELD10 BIOSCIENCE, INC. (YTEN) Delisted Director 2,026 $0.35 $709 $0 34 2024-04-01
ACHILLION PHARMACEUTICALS INC (ACHN) Delisted Director 0 — — $0 13 2020-01-29
YIELD10 BIOSCIENCE, INC. (MBLX) Delisted Director 31,250 — — $21.4K 11 2015-09-14
ACHILLION PHARMACEUTICALS INC (TPTX) Delisted Director — $76.01 — $0 4 2008-12-17

Recent Filings

138 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-09 SLS Grant (A) +50,000 $0 EDGAR
2025-06-13 SLS Buy (P) +10,000 $14.8K EDGAR
2025-04-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Disp (D) −11,340 -$1.50M EDGAR
2025-01-14 SLS Grant (A) +12,500 $0 EDGAR
2024-07-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Grant (A) +83 $5.7K EDGAR
2024-06-25 Intra-Cellular Therapies, Inc. (ITCI) Delisted Exer (M) +1,567 $0 EDGAR
2024-06-21 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed — -$1.18M EDGAR
2024-06-18 — Notice (144) −20,000 -$1.52M EDGAR
2024-06-18 Intra-Cellular Therapies, Inc. (ITCI) Delisted Grant (A) — $0 EDGAR
2024-04-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Grant (A) +79 $5.5K EDGAR
Showing 1–10 of 138
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.